Top

Published in:

01-03-2015 | Surgical Symposium Contribution

Minimally Invasive Esophagectomy for Dysplastic Barrett’s Esophagus

Authors: Sheraz R. Markar, George Hanna

Published in: World Journal of Surgery | Issue 3/2015

Abstract

A substantial portion of patients diagnosed preoperatively with high grade dysplasia (HGD) alone will have occult esophageal adenocarcinoma on analysis of the surgical specimen. Therefore, because of an increased risk of disease progression and malignancy, patients with HGD should be referred for esophagectomy promptly when endoscopic therapy has failed. The required extent of lymphadenectomy in this cohort of patients is unknown because of the variable incidence of submucosal cancer observed. Improvements in perioperative care, adoption of a minimally invasive surgical approach, and centralization of esophageal cancer services have substantially reduced the rates of mortality and morbidity associated with esophagectomy in recent years. Minimally invasive esophagectomy should be considered the treatment of choice in patients with dysplastic Barrett’s esophagus that is refractory to endoscopic therapy or those at high risk of invasive cancer.

Simard EP, Ward EM, Siegel R et al (2012) Cancers with increasing incidence trends in the United States: 1999 through 2009. CA Cancer J Clin 62:118–129CrossRefPubMed

Lagergren J, Bergstrom R, Nyren O (1999) Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130:883–890CrossRefPubMed

Lagergren J, Bergstrom R, Lindgren A et al (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831CrossRefPubMed

Korst RJ, Altorki NK (2003) High grade dysplasia: surveillance, mucosal ablation, or resection? World J Surg 27:1030–1034. doi:10.1007/s00268-003-7057-x CrossRefPubMed

Reid BJ, Haggitt RC, Rubin CE et al (1988) Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol 19:166–178CrossRefPubMed

Rastogi A, Puli S, El-Serag HB et al (2008) Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 67:394–398CrossRefPubMed

Downs-Kelly E, Mendelin JE, Bennett AE et al (2008) Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies. Am J Gastroenterol 103:2333–2340CrossRefPubMed

Bennett C, Vakil N, Bergman J et al (2012) Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143:336–346CrossRefPubMed

Overholt BF, Lightdale CJ, Wang KK et al (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62:488–498CrossRefPubMed

10.

Shaheen NH, Sharma P, Overholt BF et al (2009) Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 360:2277–2288CrossRefPubMed

11.

Wu J, Pan YM, Wang TT et al (2014) Endotherapy versus surgery for early neoplasia in Barrett’s esophagus: a meta-analysis. Gastrointest Endosc 79:233–241CrossRefPubMed

12.

Varghese TK Jr, Wood DE, Farjah F et al (2011) Variation in esophagectomy outcomes in hospitals meeting Leapfrog volume outcome standards. Ann Thorac Surg 91:1003–1009CrossRefPubMed

13.

Finks JF, Osbourne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128–2137CrossRefPubMedPubMedCentral

14.

Briez N, Piessen G, Torres F et al (2012) Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. Br J Surg 99:1547–1553CrossRefPubMed

15.

Biere SS, van Berge Henegouwen MI, Maas KW et al (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 379:1887–1892CrossRefPubMed

16.

Ancona E, Rampado S, Cassaro M et al (2008) Prediction of lymph node status is superficial esophageal carcinoma. Ann Surg Oncol 15:3278–3288CrossRefPubMed

17.

Lorenz D, Origer J, Pauthner M et al (2014) Prognostic risk factors of early esophageal adenocarcinomas. Ann Surg 259:469–476CrossRefPubMed

18.

Leers JM, DeMeester SR, Oezcelik A et al (2011) The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 253:271–278CrossRefPubMed

19.

Liu L, Hofstetter W, Rashid A et al (2005) Significance of the depth of tumor invasion in early (T1) esophageal adenocarcinoma. Am J Surg Pathol 29:1079–1085PubMed

20.

Bergergon EJ, Lin J, Chang AC et al (2014) Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies. J Thorac Cardiovasc Surg 147:765–773CrossRef

21.

Konda VJ, Ross AS, Ferguson MK et al (2008) Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett’s esophagus overestimated? Clin Gastroenterol Hepatol 6:159–164CrossRefPubMed

22.

Buttar NS, Wang KK, Sebo TJ et al (2001) Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology 120:1630–1639CrossRefPubMed

23.

Konda VJ, Ferguson MK (2010) Esophageal resection for high-grade dysplasia and intramucosal carcinoma: when and how? World J Gastroenterol 16:3786–3792CrossRefPubMedPubMedCentral

24.

Hunt BM, Louie BE, Dunst CM et al (2014) Esophagectomy for failed endoscopic therapy in patients with high-grade dysplasia or intramucosal carcinoma. Dis Esophagus 27:362–367CrossRefPubMed

25.

Hulscher JB, Tijssen JG, Obertop H et al (2001) Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 72:306–313CrossRefPubMed

26.

Chang AC, Ji H, Birkmeyer NJ et al (2008) Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 85:424–429CrossRefPubMed

27.

Dar MS, Goldblum JR, Rice TW et al (2003) Can extent of high grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma in oesophagectomy? Gut 52:486–489CrossRefPubMedPubMedCentral

28.

Fernando HC, Luketich JD, Buenaventura PO et al (2002) Outcomes of minimally invasive esophagectomy (MIE) for high-grade dysplasia of the esophagus. Eur J Cardiothorac Surg 22:1–6CrossRefPubMed

29.

Kariv R, Plesec TP, Goldblum JR et al (2009) The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol 7:653–658CrossRefPubMed

30.

Mirnezami R, Rohatgi A, Sutcliffe RP et al (2009) Transhiatal oesophagectomy: treatment of choice for high-grade dysplasia. Eur J Cardiothorac Surg 36:364–367CrossRefPubMed

31.

Prasad GA, Buttar NS, Wongkeesong LM et al (2007) Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett’s esophagus. Am J Gastroenterol 102:2380–2386CrossRefPubMedPubMedCentral

32.

Romagnoli R, Collard JM, Gutschow C et al (2003) Outcomes of dysplasia arising in Barrett’s esophagus: a dynamic view. J Am Coll Surg 197:365–371CrossRefPubMed

33.

Reed MR, Tolis G Jr, Edil BH et al (2005) Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg 79:1110–1115CrossRefPubMed

34.

Rice TW, Blackstone EH, Goldblum JR et al (2001) Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc 122:1077–1090CrossRef

35.

Sujendran V, Sica G, Warren B et al (2005) Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett’s oesophagus. Eur J Cardiothorac Surg 28:763–766CrossRefPubMed

36.

Thomson BN, Cade RJ (2003) Oesophagectomy for early adenocarcinoma and dysplasia arising in Barrett’s oesophagus. ANZ J Surg 73:121–124CrossRefPubMed

37.

Tseng EE, Wu TT, Yeo CJ et al (2003) Barrett’s esophagus with high grade dysplasia: surgical results and long-term outcome–an update. J Gastrointest Surg 7:164–171CrossRefPubMed

38.

Wang VS, Hornick JL, Sepulveda JA et al (2009) Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett’s esophagus: a 20-year experience. Gastrointest Endosc 69:777–783CrossRefPubMed

39.

Waxman I, Raju GS, Critchlow J et al (2006) High-frequency probe ultrasonography has limited accuracy for detecting invasive adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma: a case series. Am J Gastroenterol 101:1773–1779CrossRefPubMed

40.

Williams VA, Watson TJ, Herbella FA et al (2007) Esophagectomy for high grade dysplasia is safe, curative and results in good alimentary outcome. J Gastrointest Surg 11:1589–1597CrossRefPubMed

41.

Zaninotto G, Parenti AR, Ruol A et al (2000) Oesophageal resection for high-grade dysplasia in Barrett’s oesophagus. Br J Surg 87:1102–1105CrossRefPubMed

42.

Holscher AH, Bollscweiller E (2014) Frequency of lymph node metastasis in submucosal esophageal cancer (letter). Ann Surg 259:e84CrossRefPubMed

43.

Mamidanna R, Bottle A, Aylin P et al (2012) Short-term outcomes following open versus minimally invasive esophagectomy for cancer in England: a population-based national study. Ann Surg 255:197–203CrossRefPubMed

44.

National Oesophago-Gastric Cancer Audit (2013) http://www.rcseng.ac.uk/media/docs/press_releases/national-oesophago-gastric-cancer-audit-2013

45.

Finks JF, Osbourne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128–2137CrossRefPubMedPubMedCentral

46.

Markar SR, Karthikesalingam A, Thrumurthy S et al (2012) Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000–2011. J Gastrointest Surg 16:1055–1063CrossRefPubMed

47.

Nguyen NT, Schauer P, Luketich JD (2000) Minimally invasive esophagectomy for Barrett’s esophagus with high-grade dysplasia. Surgery 127:284–290CrossRefPubMed

48.

Perry KA, Enestvedt CK, Pham T et al (2009) Comparison of laparoscopic inversion esophagectomy and open transhiatal esophagectomy for high-grade dysplasia and stage I esophageal adenocarcinoma. Arch Surg 144:679–684CrossRefPubMed

49.

Boshier PR, Anderson O, Hanna GB (2011) Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg 254:894–906CrossRefPubMed

50.

Jacobs M, Macefield RC, Elbers RG et al (2013) Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery. Qual Life Res 23:1097–1115CrossRefPubMed

51.

Sundaram A, Geronimo JC, Willer BL et al (2012) Survival and quality of life after minimally invasive esophagectomy: a single-surgeon experience. Surg Endosc 26:168–176CrossRefPubMed

52.

Parameswaran R, Blazeby JM, Hughes R et al (2010) Health-related quality of life after minimally invasive oesophagectomy. Br J Surg 97:525–531CrossRefPubMed

Title: Minimally Invasive Esophagectomy for Dysplastic Barrett’s Esophagus
Authors: Sheraz R. Markar
George Hanna
Publication date: 01-03-2015
Publisher: Springer US
Published in: World Journal of Surgery / Issue 3/2015
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-014-2746-1

At a glance: The STEP trials

Springer Medicine

Minimally Invasive Esophagectomy for Dysplastic Barrett’s Esophagus

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

The Utility of Neck Ultrasound and Sestamibi Scans in Patients with Secondary and Tertiary Hyperparathyroidism

The Role of Preoperative Biliary Drainage in Severely Jaundiced Patients

Barrett’s Oesophagus: A Tailored Strategy

The Underestimated Risk of Cancer in Patients with Multinodular Goiters After a Benign Fine Needle Aspiration

Prognostic Significance of Lymphovascular Invasion in Node-Negative Gastric Cancer

Definition of Barrett’s Esophagus Dysplasia: Are We Speaking the Same Language?